APEX1 and cancer: Other studies suggest APE1 inhibitors could serve as standalone agents for treating BRCA- or PTEN-deficient cancers [20–22], in a synthetic-lethal approach similar to that established for inhibitors of poly(ADP-ribose) polymerase (PARP) [23, 24], which is also a BER enzyme.